Ironwood Pharmaceuticals, Inc. (IRWD), Monday announced that the U.S. Food and Drug Administration has approved Linzess (linaclotide) as a once-daily treatment for pediatric patients ages 6-17 years old with functional constipation.
Linzess is the first and only FDA-approved prescription therapy for functional constipation in this patient population.
Earlier this year, the FDA granted a 6-month priority review to supplemental New Drug Application, 4 months earlier than the standard review timeline.
Linzess is developed and marketed by AbbVie and Ironwood Pharmaceuticals in the United States.
Functional constipation in children is a chronic condition characterized by hard, infrequent bowel movements that are often difficult or painful to pass2. The condition affects an estimated 6 million children ages 6-17 years-old in the U.S.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.